ELEV
Elevation Oncology, Inc. [ELEV] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ELEV Stock Summary
Top 10 Correlated ETFs
ELEV
Top 10 Correlated Stocks
ELEV
In the News
ELEV Financial details
Company Rating
-
Market Cap
230.12M
Income
-45.7M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
29
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-1.47
Forward P/E
-
PEG
0.23
P/S
-
P/B
1.34
P/C
-
P/FCF
-1.35
Quick Ratio
12.46
Current Ratio
12.99
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.53
EPS next Y
-
EPS next Q
-
EPS this Y
-67.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-24%
-
-
-
-
SMA20
-8.57%
SMA50
4.92%
SMA100
8.47%
Inst Own
-
Inst Trans
-
ROA
-57%
ROE
-105%
ROC
-0.61%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.363-5.89
52W High
-
52W Low
-
RSI
43.46
Rel Volume
0.63
Avg Volume
1.44M
Volume
909K
Perf Week
-0.21%
Perf Month
-26.7%
Perf Quarter
-17.24%
Perf Half Y
-25.05%
-
-
-
-
Beta
1.36
-
-
Volatility
0.02%, 0.04%
Prev Close
-6.53%
Price
0.6074
Change
-7.97%
Company Profile
- Volume Average 1.44M
- Market Capitalization 230.12M
- Employee 29
- CEO Mr. Joseph J. Ferra Jr.
- Headquarters New York,NY,US
- IPO Date 2021-06-25
-
Website
https://elevationoncology.com 
Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
